CP-870,893

Known as: CP-870893 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2015
02420062015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Data from murine models suggest that CD40 activation may synergize with cytotoxic chemotherapy. We aimed to determine… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2013
2013
CD40 is a cell-surface molecule that critically regulates immune responses. CP-870,893 is a fully human, CD40-specific agonist… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE This phase I study investigated the maximum-tolerated dose (MTD), safety, pharmacodynamics, immunologic correlatives, and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2011
2011
CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Anti-CD40 antibodies are in clinical development in patients with metastatic melanoma, a cancer that has been reported earlier to… (More)
Is this relevant?
2009
2009
CD40 activation of antigen presenting cells (APC) such as dendritic cells (DC) and B cells plays an important role in… (More)
  • table 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
2507 Background: The cell-surface molecule CD40 plays a critical role in activating antigen presenting cells (APC) and mediates… (More)
Is this relevant?
2006
2006
2539 Background: CD40 is expressed on B-cells, monocytes, dendritic cells, other normal tissues and tumors. Previous studies… (More)
Is this relevant?
2006
2006
2514 Background: CP-870,893 is a fully human IgG2 CD40 agonist antibody currently in early clinical trials. In vitro studies… (More)
Is this relevant?
2006
2006
The human monoclonal antibody CP-870,893 is a CD40 receptor agonist currently being developed for the treatment of cancer. A… (More)
  • figure 2
  • figure 1
  • figure 4
  • figure 3
  • table 1
Is this relevant?